57 related articles for article (PubMed ID: 17026790)
1. Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
Wolpin BM; Clark JW; Meyerhardt JA; Earle CC; Ryan DP; Enzinger PC; Zhu AX; Blaszkowsky L; Battu S; Fuchs CS
Clin Colorectal Cancer; 2006 Sep; 6(3):208-13. PubMed ID: 17026790
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
Meyerhardt JA; Clark JW; Supko JG; Eder JP; Ogino S; Stewart CF; D'Amato F; Dancey J; Enzinger PC; Zhu AX; Ryan DP; Earle CC; Mayer RJ; Michelini A; Kinsella K; Fuchs CS
Cancer Chemother Pharmacol; 2007 Oct; 60(5):661-70. PubMed ID: 17216531
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; Rogers T; Kelley SK; Ramies DA; Lum BL; Hidalgo M
Clin Cancer Res; 2004 Oct; 10(19):6522-7. PubMed ID: 15475439
[TBL] [Abstract][Full Text] [Related]
4. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J
J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725
[TBL] [Abstract][Full Text] [Related]
5. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
6. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
8. Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
Hanauske AR; Cassidy J; Sastre J; Bolling C; Jones RJ; Rakhit A; Fettner S; Brennscheidt U; Feyereislova A; Díaz-Rubio E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):523-31. PubMed ID: 17255274
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Hofheinz RD; Kubicka S; Wollert J; Arnold D; Hochhaus A
Onkologie; 2006 Dec; 29(12):563-7. PubMed ID: 17202826
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
[TBL] [Abstract][Full Text] [Related]
12. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
[TBL] [Abstract][Full Text] [Related]
13. Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.
Folprecht G; Tabernero J; Köhne CH; Zacharchuk C; Paz-Ares L; Rojo F; Quinn S; Casado E; Salazar R; Abbas R; Lejeune C; Marimón I; Andreu J; Ubbelohde U; Cortes-Funes H; Baselga J
Clin Cancer Res; 2008 Jan; 14(1):215-23. PubMed ID: 18172273
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Veronese ML; Sun W; Giantonio B; Berlin J; Shults J; Davis L; Haller DG; O'Dwyer PJ
Br J Cancer; 2005 May; 92(10):1846-9. PubMed ID: 15870719
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Starling N; Vázquez-Mazón F; Cunningham D; Chau I; Tabernero J; Ramos FJ; Iveson TJ; Saunders MP; Aranda E; Countouriotis AM; Ruiz-Garcia A; Wei G; Tursi JM; Guillen-Ponce C; Carrato A
Ann Oncol; 2012 Jan; 23(1):119-127. PubMed ID: 21447616
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Ogino S; Meyerhardt JA; Cantor M; Brahmandam M; Clark JW; Namgyal C; Kawasaki T; Kinsella K; Michelini AL; Enzinger PC; Kulke MH; Ryan DP; Loda M; Fuchs CS
Clin Cancer Res; 2005 Sep; 11(18):6650-6. PubMed ID: 16166444
[TBL] [Abstract][Full Text] [Related]
17. A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.
Santoro A; Comandone A; Rimassa L; Granetti C; Lorusso V; Oliva C; Ronzoni M; Siena S; Zuradelli M; Mari E; Pressiani T; Carnaghi C
Ann Oncol; 2008 Nov; 19(11):1888-93. PubMed ID: 18667394
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?
Zampino MG; Magni E; Santoro L; Zorzino L; Dell'Orto P; Sonzogni A; Fazio N; Monfardini L; Chiappa A; Biffi R; de Braud F
Cancer Chemother Pharmacol; 2008 Dec; 63(1):139-48. PubMed ID: 18327586
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.
Cho CD; Fisher GA; Halsey J; Sikic BI
Invest New Drugs; 2006 Mar; 24(2):117-23. PubMed ID: 16683204
[TBL] [Abstract][Full Text] [Related]
20. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
Midgley RS; Kerr DJ; Flaherty KT; Stevenson JP; Pratap SE; Koch KM; Smith DA; Versola M; Fleming RA; Ward C; O'Dwyer PJ; Middleton MR
Ann Oncol; 2007 Dec; 18(12):2025-9. PubMed ID: 17846021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
